GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of someone explain FLOW to me like I have not read a paper in years — 51 comments in the full submission. View in context.
2k
c/trialwatch·submitted 6 months ago by u/nordic_pricing

someone explain FLOW to me like I have not read a paper in years

Discussionbranch of 7 comments

someone explain FLOW to me like I have not read a paper in years. Searched first, found three threads that contradict each other, hence the post. The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table. Compared myself to a trial mean for about six months…

Read the full submission and all 51 comments →

This branch

7 comments, started 6 months ago
u/cesar_ivaturi360 points·6 months ago

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

replysharereportpermalink
u/hazard_ratio_halMOD213 points·6 months ago

Added the trial identifier to the title so this thread is findable in two years.

replysharereportpermalink
u/iman_castellanos400 points·6 months ago

trial populations get support that nobody on this board gets

replysharereportpermalink
u/nhs_waitlist_nUK142 points·6 months ago

trial populations get support that nobody on this board gets

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

replysharereportpermalink
u/receipts_or_nothingvetting77 points·6 months ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/ewan_tulloch72 points·6 months ago

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

replysharereportpermalink
u/zaid_roos59 points·6 months ago·edited

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.